Drug Profile


Alternative Names: CM 4307

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suzhou Zelgen Biopharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II/III Hepatocellular carcinoma
  • Phase II Thyroid cancer
  • Phase I/II Gastric cancer; Oesophageal cancer
  • Phase I Nasopharyngeal cancer

Most Recent Events

  • 01 Dec 2016 Phase-III clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in China (PO) (NCT02870582)
  • 01 Sep 2016 Phase-II clinical trials in Thyroid cancer in China (PO) (NCT02870569)
  • 12 Aug 2016 Suzhou Zelgen Biopharmaceuticals plans a phase II trial in Thyroid cancer in China (NCT02870569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top